MiMedx Group (MDXG) Affirms Q2 Guidance

MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016, as well as a reminder that the annual meeting will be at the newer MiMedx facility located at 1828 West Oak Parkway, Marietta, Georgia. This facility is in the same business park as the MiMedx corporate headquarters and is located near the middle of the business park approximately one-half mile from the Company's main office.

Following conclusion of the formal part of the meeting, management will conduct an abbreviated version of its investor presentation followed by a question and answer session.

Parker H. "Pete" Petit, Chairman and CEO, said, "We are looking forward to seeing many of our investors tomorrow and to answering their questions. I am sure a few of the questions will relate to the implementation of our new sales management system ("SMS") and whether the issues we experienced in the first quarter have been resolved. I am happy to announce that all indicators denote that the vast majority of the issues have been addressed, and we appear to be back to business as usual. We are pleased with our revenue trends through the first half of the quarter, and our overall revenue has developed as we anticipated. I believe this is a clear indication that all of the development and training activity we put into our new SMS is beginning to increase our sales efficiencies. This system will become one of the Company's major assets, and I believe it will prove to be extremely effective in allowing us to maintain our leadership role in all aspects of our product offerings."

"At this point, we are reiterating the guidance we provided in April, and continue to expect second quarter of 2016 revenue to be in the range of $55.7 million to $57.0 million," concluded Petit.

You May Also Be Interested In

• Texas Instruments (TXN) jumps as on earnings, revenue beat in fiscal Q1
• Day One Biopharmaceuticals' (DAWN) OJEMDA Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
• Visa (V) earnings and revenue exceed estimates in Q2, shares rise